QUEBEC CITY, Nov. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that it has entered the second stage of patient recruitment for its Phase 2 trial in endometrial cancer with AEZS-108, a luteinizing hormone-releasing hormone (LHRH) agonist linked to doxorubicin. The decision to enter the second stage of patient recruitment was taken following recent first stage data reporting 1 complete response (CR) and 2 partial responses (PR) among 14 patients with a diagnosis of disseminated endometrial cancer. The trial is part of a Phase 2 program in gynaecological cancers for which patient enrolment began in December 2007. The open-label, non-comparative multi-center Phase 2 program will treat up to 82 women with LHRH-receptor positive ovarian and endometrial cancerous tumors. The primary endpoint for the program is the partial or complete tumor response rate according to Response Evaluation Criteria in Solid Tumors (RECIST) and/or Gynaecologic Cancer Intergroup (GCIG) guidelines. The program is being conducted in 15 centers in Europe under the supervision of lead investigator, Prof. Gnter Emons, M.D., of the Georg-August-University, Institute of Gynaecology and Obstetrics in Gttingen, Germany.
On October 2, 2008, the Company announced it had entered the second stage of patient recruitment, this time for the Phase 2 trial in ovarian cancer of this very same program, after first stage data had shown two partial responses (PR).
Paul Blake, M.D., Senior Vice President and Chief Medical Officer of
AEterna Zentaris commented, "We are very pleased with this additional data
on the early signal of potential efficacy of our l
|SOURCE AETERNA ZENTARIS INC.|
Copyright©2008 PR Newswire.
All rights reserved